JP2015523074A - 組換えイズロン酸２スルファターゼの製造方法 - Google Patents

組換えイズロン酸２スルファターゼの製造方法 Download PDF

Info

Publication number
JP2015523074A
JP2015523074A JP2015520577A JP2015520577A JP2015523074A JP 2015523074 A JP2015523074 A JP 2015523074A JP 2015520577 A JP2015520577 A JP 2015520577A JP 2015520577 A JP2015520577 A JP 2015520577A JP 2015523074 A JP2015523074 A JP 2015523074A
Authority
JP
Japan
Prior art keywords
protein
recombinant
cell
cells
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015520577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523074A5 (enExample
Inventor
チュン ザン，
チュン ザン，
フェレンク ボルドッグ，
フェレンク ボルドッグ，
Original Assignee
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド, シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド filed Critical シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド
Publication of JP2015523074A publication Critical patent/JP2015523074A/ja
Publication of JP2015523074A5 publication Critical patent/JP2015523074A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015520577A 2012-06-29 2013-06-28 組換えイズロン酸２スルファターゼの製造方法 Pending JP2015523074A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666712P 2012-06-29 2012-06-29
US61/666,712 2012-06-29
PCT/US2013/048601 WO2014005036A1 (en) 2012-06-29 2013-06-28 Method of producing recombinant iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
JP2015523074A true JP2015523074A (ja) 2015-08-13
JP2015523074A5 JP2015523074A5 (enExample) 2016-08-12

Family

ID=49778402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520577A Pending JP2015523074A (ja) 2012-06-29 2013-06-28 組換えイズロン酸２スルファターゼの製造方法

Country Status (21)

Country Link
US (1) US20140004097A1 (enExample)
EP (1) EP2867367A4 (enExample)
JP (1) JP2015523074A (enExample)
KR (1) KR20150037908A (enExample)
CN (1) CN104583414A (enExample)
AU (1) AU2013282417A1 (enExample)
BR (1) BR112014032544A2 (enExample)
CA (1) CA2877492A1 (enExample)
CL (1) CL2014003569A1 (enExample)
CO (1) CO7240395A2 (enExample)
CR (1) CR20140587A (enExample)
DO (1) DOP2014000297A (enExample)
EA (1) EA201492185A1 (enExample)
HK (2) HK1209790A1 (enExample)
IL (1) IL236324A0 (enExample)
IN (1) IN2014DN11272A (enExample)
MX (1) MX2015000188A (enExample)
PE (1) PE20150603A1 (enExample)
PH (1) PH12014502870A1 (enExample)
SG (1) SG11201408755TA (enExample)
WO (1) WO2014005036A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524662A (ja) * 2012-07-31 2015-08-27 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
ES2762672T3 (es) * 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
JP6785777B2 (ja) 2015-02-05 2020-11-18 アール．ピー． シェーラー テクノロジーズ エルエルシー 活性化ホルミルグリシン生成酵素ならびにその生成方法及び使用方法
KR20180063179A (ko) * 2015-10-07 2018-06-11 조엘 후이젠가 인간의 노화에 따른 노쇠의 방어 및 회복을 위한 생체 경로의 복구
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
CN109689191B (zh) * 2016-07-25 2021-11-19 瑞普利金公司 交替切向流快速收获
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517412A (ja) * 2003-02-11 2006-07-27 トランスカリヨティック セラピーズ インコーポレーテッド 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療
JP2011509674A (ja) * 2008-01-18 2011-03-31 バイオマリン ファーマシューティカル インコーポレイテッド 高度にリン酸化された活性なヒトリソソームスルファターゼ酵素の製造およびそれの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
DE60032349T2 (de) * 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
EP2267024B1 (en) * 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US7888101B2 (en) * 2005-12-08 2011-02-15 Amgen Inc. Host cells comprising alpha 1,2 mannosidase and culture methods thereof
ES2725200T3 (es) * 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517412A (ja) * 2003-02-11 2006-07-27 トランスカリヨティック セラピーズ インコーポレーテッド 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療
JP2011509674A (ja) * 2008-01-18 2011-03-31 バイオマリン ファーマシューティカル インコーポレイテッド 高度にリン酸化された活性なヒトリソソームスルファターゼ酵素の製造およびそれの使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524662A (ja) * 2012-07-31 2015-08-27 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法

Also Published As

Publication number Publication date
EP2867367A1 (en) 2015-05-06
PH12014502870A1 (en) 2015-02-23
CN104583414A (zh) 2015-04-29
CA2877492A1 (en) 2014-01-03
EA201492185A1 (ru) 2015-10-30
AU2013282417A1 (en) 2015-01-29
BR112014032544A2 (pt) 2017-08-01
WO2014005036A1 (en) 2014-01-03
MX2015000188A (es) 2015-04-08
DOP2014000297A (es) 2015-04-15
HK1209458A1 (en) 2016-04-01
IN2014DN11272A (enExample) 2015-10-09
CL2014003569A1 (es) 2015-04-17
HK1209790A1 (en) 2016-04-08
IL236324A0 (en) 2015-02-26
CR20140587A (es) 2015-04-06
KR20150037908A (ko) 2015-04-08
US20140004097A1 (en) 2014-01-02
CO7240395A2 (es) 2015-04-17
EP2867367A4 (en) 2016-02-24
PE20150603A1 (es) 2015-05-27
SG11201408755TA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
AU2018200710B2 (en) Cells for producing recombinant iduronate-2-sulfatase
JP2015523074A (ja) 組換えイズロン酸２スルファターゼの製造方法
JP7119181B2 (ja) 生産性向上のためのｒｎａ関連酵素の修飾
AU2016201487B2 (en) Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
JP2018531017A6 (ja) 生産性向上のためのｒｎａ関連酵素の修飾
EA044790B1 (ru) Клетки для получения рекомбинантной идуронат-2-сульфатазы
HK1209651B (en) Cells for producing recombinant iduronate-2-sulfatase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180720